River Edge, NJ, United States of America

Kaushik Dutta

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Kaushik Dutta: Pioneering Antibody Conjugation Processes

Introduction

Kaushik Dutta, an inventive mind from River Edge, NJ, has made significant contributions to the realm of therapeutic protein engineering. With a focus on optimizing the production of antibody cysteines, his work is pivotal in advancing the field of antibody-drug conjugates (ADCs).

Latest Patents

Dutta holds a patent titled "Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation." This patent details a method for enhancing the production of selectively capped and uncapped cysteines on antibodies. By carefully manipulating cell growth conditions, such as the depletion of cysteine in the cell culture process, he aims to achieve efficient production of therapeutic proteins, including ADCs. The innovative process also involves conjugating a TNB-capped cysteine-containing protein with a reducing agent, successfully detaching the TNB-capping moieties while preserving crucial antibody inter-chain sulfur bonds.

Career Highlights

Kaushik Dutta is currently employed at Pfizer Corporation, where his expertise is utilized in the development of advanced therapeutic solutions. His innovative contributions are shaping the direction of the company’s research initiatives and product development strategies.

Collaborations

Throughout his career, Dutta has worked alongside distinguished colleagues, including Jose Manuel Gomes and Frank W. Kotch. Together, they collaborate to push the boundaries of scientific research in protein conjugation, driving the field forward with their combined expertise.

Conclusion

Kaushik Dutta exemplifies the spirit of innovation within the pharmaceutical industry. His patented processes for antibody cysteine production showcase his dedication to improving therapeutic methodologies. As he continues to work at Pfizer Corporation, his contributions are set to enhance the landscape of drug development, making a significant impact on patient care and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…